Insider Selling: Karyopharm Therapeutics Inc (NASDAQ:KPTI) CEO Sells 10,000 Shares of Stock

Share on StockTwits

Karyopharm Therapeutics Inc (NASDAQ:KPTI) CEO Michael Kauffman sold 10,000 shares of the company’s stock in a transaction dated Monday, December 9th. The shares were sold at an average price of $17.02, for a total value of $170,200.00. Following the transaction, the chief executive officer now directly owns 539,767 shares in the company, valued at $9,186,834.34. The sale was disclosed in a filing with the SEC, which is available through this link.

Michael Kauffman also recently made the following trade(s):

  • On Friday, November 8th, Michael Kauffman sold 10,000 shares of Karyopharm Therapeutics stock. The shares were sold at an average price of $14.63, for a total value of $146,300.00.
  • On Monday, November 11th, Michael Kauffman sold 10,000 shares of Karyopharm Therapeutics stock. The shares were sold at an average price of $14.76, for a total value of $147,600.00.
  • On Friday, November 1st, Michael Kauffman sold 20,000 shares of Karyopharm Therapeutics stock. The shares were sold at an average price of $14.17, for a total value of $283,400.00.
  • On Monday, September 16th, Michael Kauffman sold 10,000 shares of Karyopharm Therapeutics stock. The shares were sold at an average price of $12.00, for a total value of $120,000.00.

Shares of KPTI stock traded down $0.07 during mid-day trading on Friday, reaching $16.93. The stock had a trading volume of 64,956 shares, compared to its average volume of 1,143,735. The business’s fifty day moving average is $14.99 and its 200-day moving average is $10.08. The company has a current ratio of 7.16, a quick ratio of 7.16 and a debt-to-equity ratio of 2.03. The firm has a market cap of $1.05 billion, a price-to-earnings ratio of -5.39 and a beta of 2.60. Karyopharm Therapeutics Inc has a 1-year low of $3.92 and a 1-year high of $18.70.

Karyopharm Therapeutics (NASDAQ:KPTI) last announced its quarterly earnings data on Monday, November 4th. The company reported ($0.67) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.84) by $0.17. The business had revenue of $13.15 million for the quarter, compared to analyst estimates of $1.61 million. Karyopharm Therapeutics had a negative return on equity of 187.25% and a negative net margin of 909.24%. On average, analysts forecast that Karyopharm Therapeutics Inc will post -3.13 earnings per share for the current year.

Hedge funds have recently made changes to their positions in the company. Bank of Montreal Can acquired a new position in shares of Karyopharm Therapeutics in the second quarter valued at about $29,000. Tower Research Capital LLC TRC increased its holdings in shares of Karyopharm Therapeutics by 536.6% in the third quarter. Tower Research Capital LLC TRC now owns 3,476 shares of the company’s stock valued at $34,000 after purchasing an additional 2,930 shares during the period. Envestnet Asset Management Inc. increased its holdings in shares of Karyopharm Therapeutics by 12.4% in the second quarter. Envestnet Asset Management Inc. now owns 11,980 shares of the company’s stock valued at $72,000 after purchasing an additional 1,319 shares during the period. Virtu Financial LLC acquired a new position in shares of Karyopharm Therapeutics in the third quarter valued at about $99,000. Finally, Commonwealth Equity Services LLC acquired a new position in shares of Karyopharm Therapeutics in the third quarter valued at about $124,000. 93.14% of the stock is currently owned by institutional investors and hedge funds.

Several research analysts recently issued reports on KPTI shares. ValuEngine lowered Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, December 3rd. Robert W. Baird set a $25.00 target price on Karyopharm Therapeutics and gave the company a “buy” rating in a research report on Tuesday, September 24th. Zacks Investment Research raised Karyopharm Therapeutics from a “hold” rating to a “buy” rating and set a $17.00 target price on the stock in a research report on Wednesday, November 13th. Wedbush upped their target price on Karyopharm Therapeutics from $15.00 to $18.00 in a research report on Wednesday, November 6th. Finally, Canaccord Genuity reissued a “buy” rating and issued a $22.00 price objective on shares of Karyopharm Therapeutics in a report on Thursday. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and seven have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $19.86.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc (Nasdaq: KPTI) is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for
the treatment of cancer and other major diseases. Karyopharm’s SINE compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1).

Featured Article: How to invest using market indexes

Insider Buying and Selling by Quarter for Karyopharm Therapeutics (NASDAQ:KPTI)

Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Westrock Co  Position Increased by Strs Ohio
Westrock Co Position Increased by Strs Ohio
Strs Ohio Lowers Holdings in Vistra Energy Corp
Strs Ohio Lowers Holdings in Vistra Energy Corp
Centurylink Inc  Shares Sold by Valeo Financial Advisors LLC
Centurylink Inc Shares Sold by Valeo Financial Advisors LLC
Strs Ohio Increases Stock Position in Ameris Bancorp
Strs Ohio Increases Stock Position in Ameris Bancorp
Nuance Communications Inc.  Shares Purchased by Strs Ohio
Nuance Communications Inc. Shares Purchased by Strs Ohio
Exelon Co.  Shares Sold by Strs Ohio
Exelon Co. Shares Sold by Strs Ohio


 
© 2006-2020 Zolmax.